Mutant prevention concentrations, in vitro resistance evolution dynamics, and mechanisms of resistance to imipenem and imipenem/relebactam in carbapenem-susceptible Klebsiella pneumoniae isolates showing ceftazidime/avibactam resistance.

doi:10.1128/aac.01120-24

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Community

Back to search

Article

Mutant prevention concentrations, in vitro resistance evolution dynamics, and mechanisms of resistance to imipenem and imipenem/relebactam in carbapenem-susceptible Klebsiella pneumoniae isolates showing ceftazidime/avibactam resistance.

Antimicrobial agents and chemotherapy - 5 Dec 2024

Blanco-Martín Tania, González-Pinto Lucía, Aja-Macaya Pablo, Rodríguez-Pallares Salud, Sánchez-Peña Lucía, Gato Eva, Fernández-López María Del Carmen, Outeda-García Michelle, Rodríguez-Coello Arianna, Pedraza-Merino Rosa, Alonso-García Isaac, Vázquez-Ucha Juan Carlos, Martínez-Martínez Luis, Arca-Suárez Jorge, Beceiro Alejandro, Bou Germán

Abstract excerpt

Klebsiella pneumoniae carbapenemase (KPC) variants selected during ceftazidime/avibactam treatment usually develop susceptibility to carbapenems and carbapenem/β-lactamase inhibitors, such as imipenem and imipenem/relebactam. We analyzed imipenem and imipenem/relebactam single-step mutant frequencies, resistance development trajectories and differentially selected resistance mechanisms using two representative K....

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Azabicyclo Compounds

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to beta-Lactamase Inhibitors

Share to Carbapenems

Share to Ceftazidime

Share to Imipenem

Share to Klebsiella Infections

Share to Klebsiella pneumoniae

Share to Porins

Source

Open in PubMed Open full text

Identifiers

PMID: 39545736
DOI: 10.1128/aac.01120-24
PMCID: PMC11619344

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 8 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Mutant prevention concentrations, in vitro resistance evolution dynamics, and mechanisms of resistance to imipenem and imipenem/relebactam in carbapenem-susceptible Klebsiella pneumoniae isolates showing ceftazidime/avibactam resistance.PMID 39545736Read ↗

In vitro development of imipenem/relebactam resistance in KPC-producing Klebsiella pneumoniae involves multiple mutations including OmpK36 disruption and KPC modification.Semantic proximity Read ↗

Addressing therapeutic options for KPC-3-producing ST307-Klebsiella pneumoniae: insights from in vitro evolution and mutant prevention strategies.Semantic proximity Read ↗

Increased bla KPC Copy Number and OmpK35 and OmpK36 Porins Disruption Mediated Resistance to Imipenem/Relebactam and Meropenem/Vaborbactam in a KPC-Producing Klebsiella pneumoniae Clinical IsolateSemantic proximity Read ↗

Dynamic evolution of imipenem/relebactam resistance in a KPC-producing Klebsiella pneumoniae from a single patient during ceftazidime/avibactam-based treatmentsSemantic proximity Read ↗

Activity of imipenem/relebactam against KPC-producing Klebsiella pneumoniae and the possible role of Ompk36 mutation in determining resistance: an Italian retrospective analysisSemantic proximity Read ↗

Impact ofompk36genotype and KPC subtype on thein vitroactivity of ceftazidime/avibactam, imipenem/relebactam and meropenem/vaborbactam against KPC-producingK. pneumoniaeclinical isolatesSemantic proximity Read ↗

In vivo development of resistance to novel β-lactam/β-lactamase inhibitor combinations in KPC-producing Klebsiella pneumoniae infections: a case seriesSemantic proximity Read ↗

In vivo Selection of Imipenem Resistance Among Ceftazidime-Avibactam-Resistant, Imipenem-Susceptible Klebsiella pneumoniae Isolate With KPC-33 CarbapenemaseSemantic proximity Read ↗

Genomic and molecular characterisation of a <i>Klebsiella pneumoniae</i> clinical isolate resistant to meropenem-vaborbactam, imipenem-relebactam, and ceftazidime-avibactamSemantic proximity Read ↗

Stepwise KPC mutational accumulation confers high-level ceftazidime-avibactam resistance in ST11 carbapenem-resistant Klebsiella pneumoniae.Semantic proximity Read ↗

Mutant prevention concentrations and phenotypic and genomic profiling of first-step resistance mechanisms to classical and novel β-lactams in Pseudomonas aeruginosaSemantic proximity Read ↗

KPC-33 and ompK37 mutations: Unraveling the mechanism of ceftazidime/avibactam resistance in ST11 carbapenem-resistant Klebsiella pneumoniae.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.